Search research articles
Contact Us
Filters
Showing results (91-100 of 320) with videos related to
Page
of 32
Sort By:
Cell Reports
|
December 22, 2015
RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability
Edwin Chen, Jong Sook Ahn, David B Sykes, et al.
Haematologica
|
December 1, 2022
Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis
Shai Shimony, Alon Rozental, Jan P Bewersdorf, et al.
Cancer
|
October 27, 2020
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma
Gautam Borthakur, Giovanni Martinelli, Emmanuel Raffoux, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804
Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.
Current Medical Research and Opinion
|
April 29, 2011
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
James E Signorovitch, Eric Q Wu, Keith A Betts, et al.
Journal of Geriatric Oncology
|
June 16, 2015
Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults
K Rebecca Fega, Gregory A Abel, Gabriela Motyckova, et al.
Oncotarget
|
March 10, 2016
Insulin receptor substrate 1 is a substrate of the Pim protein kinases
Jin H Song, Sathish K R Padi, Libia A Luevano, et al.
Blood Reviews
|
March 16, 2024
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?
Geoffrey L Uy, Daniel J DeAngelo, Jay N Lozier, et al.
Leukemia
|
March 28, 2024
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
Shai Shimony, Jacqueline S Garcia, Julia Keating, et al.
American Journal of Hematology
|
August 19, 2011
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop
Tariq I Mughal, Jerald P Radich, Richard A Van Etten, et al.
Page
of 32
Search research articles
Search
Showing results (91-100 of 320) with videos related to
Sort By:
Page
of 32
Cell Reports
|
December 22, 2015
RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability
Edwin Chen, Jong Sook Ahn, David B Sykes, et al.
Haematologica
|
December 1, 2022
Investigational venetoclax combination therapy in acute myeloid leukemia - a systematic review and meta-analysis
Shai Shimony, Alon Rozental, Jan P Bewersdorf, et al.
Cancer
|
October 27, 2020
Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma
Gautam Borthakur, Giovanni Martinelli, Emmanuel Raffoux, et al.
Cancer Chemotherapy and Pharmacology
|
August 2, 2008
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804
Richard M Stone, Kathleen A Donohue, Wendy Stock, et al.
Current Medical Research and Opinion
|
April 29, 2011
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials
James E Signorovitch, Eric Q Wu, Keith A Betts, et al.
Journal of Geriatric Oncology
|
June 16, 2015
Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults
K Rebecca Fega, Gregory A Abel, Gabriela Motyckova, et al.
Oncotarget
|
March 10, 2016
Insulin receptor substrate 1 is a substrate of the Pim protein kinases
Jin H Song, Sathish K R Padi, Libia A Luevano, et al.
Blood Reviews
|
March 16, 2024
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?
Geoffrey L Uy, Daniel J DeAngelo, Jay N Lozier, et al.
Leukemia
|
March 28, 2024
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients
Shai Shimony, Jacqueline S Garcia, Julia Keating, et al.
American Journal of Hematology
|
August 19, 2011
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop
Tariq I Mughal, Jerald P Radich, Richard A Van Etten, et al.
Page
of 32